REGγ regulates ERα degradation via ubiquitin-proteasome pathway in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• REGγ is a proteasome coactivator involved in cellular proteolytic activity.
• Elevated REGγ expression is observed in various human carcinomas, but its role in cancer pathogenesis remains unclear.
• Estrogen receptor alpha (ERα) is a key factor in many breast cancers.

Purpose of the Study:

• To investigate the role of REGγ in breast cancer development and progression.
• To determine the correlation between REGγ expression and clinical features, including ERα status and patient survival.
• To elucidate the molecular mechanism linking REGγ and ERα in breast cancer.

Main Methods:

• Analysis of REGγ expression in 200 human breast cancer specimens.
• Cell culture studies using MCF7 and BT474 breast cancer cell lines with REGγ knockdown.
• Investigation of ERα protein degradation via the ubiquitin-proteasome pathway.

Main Results:

• REGγ was highly expressed in breast cancers and positively correlated with ERα status.
• REGγ expression was associated with poor clinical features and reduced survival rates in ERα-positive breast cancer patients.
• REGγ knockdown significantly decreased proliferation, motility, and invasion of breast cancer cells.
• REGγ was shown to indirectly regulate ERα protein degradation through the ubiquitin-proteasome pathway.

Conclusions:

• REGγ expression is linked to ERα status and poorer prognosis in ERα-positive breast cancer.
• REGγ plays a significant role in breast cancer progression, potentially by influencing ERα stability.
• This study reveals a novel association between REGγ and ERα in breast cancer pathogenesis.